Download Citation on ResearchGate | Advances in the diagnosis, pathogenesis and treatment of CIDP | Chronic inflammatory demyelinating. This Review highlights the recent advances in diagnosing CIDP, provides an update on the immunopathology including new target antigens. CIDP is an acquired immune-mediated inflammatory disorder sometimes Advances in the diagnosis, pathogenesis and treatment of CIDP.
|Published (Last):||25 July 2012|
|PDF File Size:||14.9 Mb|
|ePub File Size:||14.67 Mb|
|Price:||Free* [*Free Regsitration Required]|
BoumpasGeorge K. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: Topics Discussed in This Paper. MRI assessment including apparent diffusion coefficient.
Advances in the diagnosis, pathogenesis and treatment of CIDP.
Skip to search form Skip to main content. From This Paper Figures, tables, and topics from this paper. An open label clinical trial of complement inhibition in multifocal motor neuropathy. Commonly used immunosuppressive drugs offer minimal benefit, necessitating the development of new therapies for treatment-refractory patients.
Advances in the diagnosis, pathogenesis and treatment of CIDP
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Immunoglobulins, Intravenous Demyelinating peripheral neuropathy Polyneuropathy. Trreatment Publications citing this paper. Showing of references.
Dalakas The Lancet Neurology Review of the evolution of electrodiagnostic criteria for chronic inflammatory demyelinating polyradicoloneuropathy.
Advances in the diagnosis, pathogenesis and treatment of CIDP – Semantic Scholar
Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy Marinos C. John David PollardPatricia J. Diagnostic insights into chronic-inflammatory demyelinating polyneuropathies.
Maintenance therapy with IVIg can induce sustained remission, increase quality of life and prevent further axonal loss, but caution is needed to avoid overtreatment. Showing of 60 extracted citations.
Brannagan Journal of the peripheral nervous system: Kenneth Craig Gorson Therapeutic advances in neurological disorders Chronic inflammatory demyelinating polyneuropathy CIDP is the most common chronic autoimmune neuropathy.
This Review highlights the recent advances in diagnosing CIDP, provides an update on the immunopathology including new target antigens, and discusses current treatments, ongoing challenges and future therapeutic directions. Bertsias Current opinion in rheumatology Despite clinical challenges in diagnosis-owing in part to the existence of disease variants, and different views on how many electrophysiological abnormalities are needed to document demyelination-consensus criteria seem to have been reached for research or clinical practice.
Current diagnosis of CIDP: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Search for additional papers on this topic. Pathogenesis and treatment of CNS lupus. Despite clinical challenges in diagnosis—owing in pathogdnesis to the existence of disease variants, and different views on how many electrophysiological abnormalities are needed to document demyelination—consensus criteria seem to have been reached for research or clinical practice.
This paper has been referenced on Twitter 1 time over the past 90 days. New biomarkers and scoring systems represent emerging tools with the potential to predict therapeutic responses and identify patients with active disease for enrollment into clinical trials. Evidence from Human and Animal Studies: References Publications referenced by this paper.
An update on the management of chronic inflammatory demyelinating polyneuropathy. Armati Journal of the peripheral nervous system: Advances in our understanding of the underlying immunopathology in CIDP have identified new targets for future therapeutic efforts, including T cells, B cells, and transmigration and transduction molecules.